Who are Rostil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Etocox, Cytotec, Indocin Sr, Joycle, Racemic Cloprostenol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rioprostil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rostil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rostil (RIOPROSTIL) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: rioprostil. Area: Pain.

phase 2 rioprostil Prostaglandin E2 receptor EP2 subtype Pain Small molecule Live · refreshed every 30 min

Target snapshot

Rostil (RIOPROSTIL). Rostil works by binding to the prostaglandin E2 receptor EP2 subtype, mimicking the action of prostaglandin E2 in the body.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rostil TARGET	RIOPROSTIL		phase 2	rioprostil	Prostaglandin E2 receptor EP2 subtype
Etocox	ETORICOXIB		marketed	etoricoxib	Mitogen-activated protein kinase 14, Prostaglandin E2 receptor EP2 subtype, Prostaglandin G/H synthase 1	2002-01-01
Cytotec	misoprostol	Generic (originally Searle/Pfizer)	marketed	Prostaglandin E1 analog	Prostaglandin E2 receptor EP2 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin E2 receptor EP4 subtype	1988-12-27
Indocin Sr	INDOMETHACIN		marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin E2 receptor EP2 subtype	1965-01-01
Joycle	diclofenac etalhyaluronate sodium	Seikagaku Corporation	marketed		Prostaglandin E2 receptor EP2 subtype
Racemic Cloprostenol	CLOPROSTENOL		marketed		Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP2 subtype, Prostaglandin E2 receptor EP3 subtype

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-04-23 — Indocin Sr · 9089471 · Method of Use · US
2030-04-23 — Indocin Sr · 8734847 · Formulation · US
2030-04-23 — Indocin Sr · 8992982 · Formulation · US

Sponsor landscape (rioprostil class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rostil — Competitive Intelligence Brief. https://druglandscape.com/ci/rioprostil. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing